Novel approaches to the management of chronic systolic heart failure: future directions and unanswered questions
- 14 June 2019
- journal article
- review article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 41 (18), 1764-1774
- https://doi.org/10.1093/eurheartj/ehz364
Abstract
Despite improvements in outcomes in the last few decades for heart failure (HF) with reduced ejection fraction (HFrEF), there still remains a need for novel therapies as many patients incompletely recover with existing therapies and progress to advanced HF. In this review, we will discuss recent advances in the management of HFrEF with a focus on upcoming therapies that hold the greatest promise for clinical use. We will discuss novel pharmacological therapies and areas of uncertainty with existing therapies. We will also discuss the potential utility and controversy surrounding novel interventions for HF such as percutaneous mitral valve repair, atrial fibrillation ablation, and other emerging interventions with positive signals for benefit in HFrEF. Finally, we will summarize the current state of stem cell and gene therapy for HFrEF and future directions.This publication has 162 references indexed in Scilit:
- Heart Failure Gene TherapyCirculation Research, 2013
- Telemonitoring in Patients with Heart FailureThe New England Journal of Medicine, 2010
- Effects of Statin Therapy According to Plasma High-Sensitivity C-Reactive Protein Concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)Circulation, 2009
- Biomarker-guided therapy in chronic heart failure: A meta-analysis of randomized controlled trialsAmerican Heart Journal, 2009
- Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID Trial), a First-in-Human Phase 1/2 Clinical TrialJournal of Cardiac Failure, 2009
- Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failureAmerican Journal of Physiology-Heart and Circulatory Physiology, 2008
- Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trialThe Lancet, 2008
- Nitroxyl Improves Cellular Heart Function by Directly Enhancing Cardiac Sarcoplasmic Reticulum Ca 2+ CyclingCirculation Research, 2007
- Left Ventricular Assist Device and Drug Therapy for the Reversal of Heart FailureThe New England Journal of Medicine, 2006
- Intracoronary Adenovirus Encoding Adenylyl Cyclase VI Increases Left Ventricular Function in Heart FailureCirculation, 2004